Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular Damage
- Conditions
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Qingwen Tao
- Target Recruit Count
- 136
- Registration Number
- NCT06519617
- Locations
- 🇨🇳
China-Japan friendship hospital, Beijing, Beijing, China
a Retrospective Study on the Systemic Treatment of LPP and FFA
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 315
- Registration Number
- NCT06512766
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Zuid-Holland, Netherlands
The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Lichen Planopilaris in Routine Clinical Care: a Patient Preference Trial
- Conditions
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 56
- Registration Number
- NCT06512753
- Locations
- 🇳🇱
Erasmus MC, Rotterdam, Zuid-Holland, Netherlands
Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss
- Conditions
- Interventions
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06467526
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-03-25
- Target Recruit Count
- 120
- Registration Number
- NCT06328387
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Hydroxychloroquine May be Beneficial for Preeclampsia
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 359
- Registration Number
- NCT06020378
The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05961202
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Incannex Healthcare Ltd
- Target Recruit Count
- 128
- Registration Number
- NCT05942911
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Emeritus Research, Sydney, New South Wales, Australia
🇦🇺Captain Sterling Medical Centre, Nedlands, Western Australia, Australia
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 155
- Registration Number
- NCT05843188
- Locations
- 🇨🇦
Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 93
- Registration Number
- NCT05842174
- Locations
- 🇺🇸
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.